ANTOLRX
  • Home
  • About Us
    • Our Vision
    • Our Team
  • Our Science
    • Approach
    • Pipeline
  • News
    • Updates
    • Articles
    • Press Releases
    • Publications
  • Contact
Select Page

Mark Carthy, CEO of AnTolRx, speaks at the World Vaccine Congress in Washington, DC

by AnTolRx | Apr 9, 2018 | Updates

World Vaccine Congress Investor Panel, April 4th “…..Mr Carthy commented that “antigen specific tolerance has the potential to deliver disease modifying therapy for  indications including autoimmune, allergies and protein drug antibody reactions. AnTolRx has...

Join us at the Antigen-Specific Immune Tolerance Drug Development Conference!

by AnTolRx | Jan 23, 2018 | Updates

Dr. Francisco J Quintana will be presenting data on AnTolRx’s antigen-specific nanoparticle platform. Join us in Boston April 24-26, 2018. http://as-immunetolerance.com

Meet us at the JP Morgan Healthcare Conference 2018!

by AnTolRx | Jan 6, 2018 | Updates

We are excited to attend the 36th annual JP Morgan Healthcare Conference in San Francisco, CA from January 8th-11th,...

Recent News

  • Francisco J Quintana, AnTolRx’s Scientific Founder, will speak next week at the international AhR meeting in Paris. August 21, 2018
  • Mark Carthy, CEO of AnTolRx, speaks at the World Vaccine Congress in Washington, DC April 9, 2018

News Archives

  • August 2018
  • April 2018
  • January 2018
  • November 2016
  • September 2016
  • August 2016

LOCATION

ANTOLRX
One Kendall Square
Building 1400 West, Suite 14303
Cambridge, MA 02139

CONTACT

Sara Tezza
sara.tezza@antolrx.com
617-902-0601

Nav

Our Vision
Our Science
Team
News

Website by &#10070OnyxWP